DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Buddy Relationships in DermatoloGic Excisions for Skin Cancer

Not Applicable

Completed

Conditions: Quality of Life
Peer Mentorship
Skin Cancer Face
Surgical Wound

Interventions: Behavioral: Peer Mentorship Program

First Posted Date: 2019-07-29

Last Posted Date: 2020-03-04

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 60

Registration Number: NCT04036344

Locations: 🇺🇸
Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

Cardiovascular Effects of CART Cell Therapy

Completed

Conditions: Leukemia
Risk Factor, Cardiovascular
Immunotherapy
Lymphoma
Cardiotoxicity

First Posted Date: 2019-07-19

Last Posted Date: 2024-10-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 44

Registration Number: NCT04026737

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin And/or Trastuzumab

Phase 1

Completed

Conditions: Toxicity Due to Chemotherapy
Cardiomyopathies
Heart Failure
Cardiotoxicity
Risk Factor, Cardiovascular
Breast Cancer

Interventions: Drug: Carvedilol

First Posted Date: 2019-07-17

Last Posted Date: 2025-01-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 69

Registration Number: NCT04023110

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Correlation of Early Postoperative Scar Appearance With Long-term Scar Outcomes

Completed

Conditions: Scar
Skin Cancer Face
Surgical Wound
Mohs Micrographic Surgery
Quality of Life

First Posted Date: 2019-07-11

Last Posted Date: 2020-04-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 113

Registration Number: NCT04015453

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Phase 2

Active, not recruiting

Conditions: Melanoma Stage III
Melanoma

Interventions: Drug: nivolumab
Drug: Ipilimumab

First Posted Date: 2019-07-10

Last Posted Date: 2024-11-05

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 67

Registration Number: NCT04013854

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Lancaster General Hospital, Lancaster, Pennsylvania, United States

A Trial of Behavioral Economic Interventions Among Food Pantry Clients

Not Applicable

Completed

Conditions: Food Preferences

Interventions: Behavioral: Behavioral economic intervention of online purchasing at a food pantry

First Posted Date: 2019-07-08

Last Posted Date: 2024-02-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 286

Registration Number: NCT04011384

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model

Completed

Conditions: Hereditary Cancer
Prostate Cancer
Genetic Predisposition to Disease
Pancreas Cancer

First Posted Date: 2019-05-02

Last Posted Date: 2025-04-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 1488

Registration Number: NCT03934606

Locations: 🇺🇸
Penn Medicine - University of Pennsylvania, Philadelphia, Pennsylvania, United States

[18F] F-GLN by PET/CT in Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Fluoroglutamine [18F]F-GLN

First Posted Date: 2019-03-05

Last Posted Date: 2025-03-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT03863457

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Cigarette Packaging of Low Nicotine Cigarettes

Not Applicable

Recruiting

Conditions: Smoking, Cigarette

Interventions: Other: LNC Cigarettes + Colored Packaging
Other: Own Brand

First Posted Date: 2019-01-14

Last Posted Date: 2024-08-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 575

Registration Number: NCT03802019

Locations: 🇺🇸
Center for Interdisciplinary Research for Nicotine Addiction, Philadelphia, Pennsylvania, United States

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Abemaciclib
Drug: Nivolumab

First Posted Date: 2018-12-20

Last Posted Date: 2022-12-14

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 7

Registration Number: NCT03781960

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy